Case Study

Ongoing Collaboration Aims To Accelerate Biosimilar Approval In China

Source: GE Healthcare Life Sciences
Ongoing Collaboration Aims To Accelerate Biosimilar Approval In China

Working with a service provider is one strategy that biosimilar manufacturers can pursue to facilitate speed to market. Implementing single-use technology is another. This case study is about how one biosimilar manufacturer is leveraging the full capabilities of GE in pursuit of achieving regulatory approval of biosimilars in China. By working with GE, Pfizer is benefiting from a global service and technology provider that is focused on building strong relationships, streamlining process transfer strategies, and implementing both single-use technologies and flexible, deployable manufacturing solutions.